Group items matching

in title, tags, annotations or url

This FOA will support research on the development of biomarkers for the complications of type 1 diabetes that will use minimally or non-invasive measures of blood vessels and nerves in the eye.  A critical obstacle for preventing and treating diabetes complications is the paucity of both biomarkers that can detect changes in blood vessels and nerves before clinical signs develop and surrogate end-points that can measure early responses to an intervention.  Given the accessibility of the blood vessels and nerves in the eye for visualization, this FOA invites applications for research using the eye to visualize the development of diabetes complications in the eye and other tissues, such as the kidney, brain, heart and peripheral nerves.      

This FOA will support research on the development of biomarkers for the complications of type 1 diabetes that will use minimally or non-invasive measures of blood vessels and nerves in the eye. A critical obstacle for preventing and treating diabetes complications is the paucity of both biomarkers that can detect changes in blood vessels and nerves before clinical signs develop and surrogate end-points that can measure early responses to an intervention. Given the accessibility of the blood vessels and nerves in the eye for visualization, this FOA invites applications for research using the eye to visualize the development of diabetes complications in the eye and other tissues, such as the kidney, brain, heart and peripheral nerves.

The purpose of this notice of funding opportunity is to identify and implement innovative strategies to better engage, detect, and manage glaucoma and other eye diseases among vulnerable populations, in community-based settings, for replication and scaling in the US. This NOFO will be accomplished with two components; Component A: Community-Based Interventions with Vulnerable Populations and Component B: Coordinating Center to provide logistics and support to the research study. Glaucoma is the leading cause of irreversible blindness among African Americans and the second leading cause of blindness worldwide. An estimated 2.2 to 2.7 million people in the United States have the disease. Due to its asymptomatic nature, half of people with glaucoma are unaware of their condition, increasing the severity of the disease. However, once detected, appropriate treatment and management can slow glaucoma progression and preserve the remaining vision, but cannot restore lost vision. Given the low general population prevalence of glaucoma, broad general population screening appears not to be cost-effective, and the marginal results from glaucoma screenings in high-risk population, it is reasonable to reach out to groups with higher prevalence (African Americans over age 40, Asians, older people [aged 65+ years] especially older Hispanics, those with a family history of glaucoma, and those with diabetes).

This funding Opportunity Announcement (FOA) encourages Multiple Principal Investigator (Multi-PD/PI) applications from United States (U.S.) and Indian institution as bilateral collaborations that will advance science and technology important to understanding, preventing, and treating blinding eye diseases, visual disorders, and their complications. Areas of Research Collaboration: Applications are encouraged from organization/institutions that propose to conduct research on the basic biology and/or genetics of ophthalmic diseases through collaborations with Indian investigators on the following: diabetic retinopathy, glaucoma, age-related macular degeneration, retinitis pigmentosa, including rare and genetic diseases such as congenital cataracts, as well as other eye conditions such as ocular inflammation/uveitis, refractive error, low vision, and corneal injury. Basic, translational, or epidemiological research maybe proposed. Clinical trials will not be supported under this FOA.

The FY18 VRP IIRA is intended to support studies that will yield highly impactful discoveries or major advancements in the research and/or patient care of eye injury and/or visual dysfunction as related to military-relevant trauma. Research projects may focus on any phase of research (e.g., basic, translational, applied, clinical, observational), excluding clinical trials. The research idea or solution should be innovative, novel, or a significant advancement over existing ideas or solutions, as applicable.

The FY18 VRP FTTSA is intended to support a highly collaborative and translational team initiative that will fundamentally advance the understanding and treatment of eye injury and/or visual dysfunction that result from a military-relevant traumatic event (e.g., blast, blunt, thermal, chemical, biological, directed energy, ionizing radiation).

The "3-D Retina Organoid'' Challenge (the "Challenge''), is an ideation Challenge in which the National Eye Institute (NEI; http://www.nei.nih.gov/), part of the National Institutes of Health (http://www.nih.gov(link is external)), is asking for ideas to maximize the physiological relevance of 3-D human retina culture systems. Currently, retina culture models do not capture the complexity of the human retina. The goal of the Challenge is to transform innovative ideas into concrete concepts to develop new in vitro 3-D human retina models that recapitulate the organization and function of the human retina. NEI intends to follow this challenge with a follow-on but distinct Reduction to Practice Challenge, which will aim to invoke scientific and technological development of the model system. Technological breakthroughs in this arena could allow researchers and physicians to better understand, diagnose, and treat retinal diseases.

The FY19 VRP Translational Research Award is intended to support translational research that moves promising discoveries into clinical applications that will advance the prevention, diagnosis, mitigation, and/or treatment of eye injury or visual dysfunction associated with military-relevant trauma. Successful applications to the FY19 VRP TRA should establish a clear path to transform a discovery into new drugs, devices, or clinical practice guidelines that are ready for definitive testing in clinical trials. It is expected that an Investigational New Drug (IND)/Investigational Device Exemption (IDE) application will be submitted during or by the end of the period of performance. Applicants are strongly encouraged to include at least one collaborator with expertise in the U.S. Food and Drug Administration (FDA) regulatory approval process on the investigative team.

The FY19 VRP IIRA is intended to support studies that will yield highly impactful discoveries or major advancements in the research and/or patient care of eye injury and/or visual dysfunction as related to military-relevant trauma. Research projects may focus on any phase of research (e.g., basic, translational, applied, clinical, observational), excluding clinical trials. The research idea or solution should be innovative or novel, or a significant advancement over existing ideas or solutions, as applicable.

The National Eye Institute (NEI) announces the reissue of PAR-10-281, "Translational Research Program (TRP) on Therapy for Visual Disorders". This program focuses on the development of novel therapies to treat visual diseases and disorders. In the context of this program, an expert develops a multi-disciplinary research team that applies an integrative approach to develop rapid and efficient translation of innovative laboratory research findings into clinical therapeutic development. It involves collaborative teams of scientists and clinicians with expertise in multiple disciplines, operating according to a clear leadership plan. Such a collaborative approach is particularly appropriate for research focused on pathways that will likely be targeted by biological intervention, such as gene therapy, cell-based therapy, and pharmacological approaches. The intention of this program is to make resources available to scientists from several disciplines to address scientific and technical questions that would be beyond the capabilities of any one research group.

CDC, in collaboration with the National AIDS Control Program/Department of AIDS Control, has successfully laid the foundation for quality standards and approaches within India's vast HIV laboratory network through a previous five-year laboratory strengthening funding opportunity announcement (FOA). Many achievements were made during the course of the five-year project period, including accreditation of national and state reference labs. This follow-on FOA is expected to build upon and sustain previous accomplishments through onsite mentoring and in service staff training with an eye to higher quality services and scale up. A plan will be developed to facilitate laboratory quality at the grassroots level for 12,000 + Integrated HIV Testing and Counseling Centers (ICTCs). This shall be done through trainer/mentor creation within the HIV laboratory network to assist peripheral laboratories in implementing minimum quality standards. Given its expanded technical assistance (TA) scope, it is also expected to build the capacity and assure quality in a phased manner for HIV related tests like CD4 enumeration, HIV viral load and STI through strengthening leadership and mentoring capacity within the laboratory network. Now in Phase IV of its HIV/AIDS response, the Government of India (GoI) is keen to address any gaps in testing coverage.

The Lions Club International Foundation (LCIF) provides funds to support public health research initiatives that evaluate and directly influence the operation of the SightFirst program, Lions' premier initiative to strengthen eye care systems in underserved communities.

Funds up to $150,000 are available for support of research directly related to blepharospasm or Meige's Syndrome, both forms of cranial dystonia M.D. or Ph.D. required for principal investigator Non-U.S. citizens, working at institutions abroad are also eligible to apply for a research grant Research proposals must relate specifically to benign essential blepharospasm and Meige to include new treatments, pathophysiology and genetics, photophobia and dry eye. If a grant is awarded, we expect a semiannual progress report Deadline to apply is August 31 each year. Grant guidelines and a listing of previous grants may be downloaded below or obtained from:

The National Eye Institute (NEI) supports large-scale clinical vision research projects, including randomized clinical trials and epidemiologic studies. At the time of submission, applications requesting support for these activities are expected to provide detailed information regarding the study rationale, design, analytic techniques, protocols and procedures, facilities and environment, organizational structure, and collaborative arrangements.

The National Eye Institute (NEI) supports investigator-initiated, complex, multi-center and other high resource risk epidemiologic studies under the cooperative agreement mechanism, UG1 activity code. Specifically, the purpose of this Funding Opportunity Announcement (FOA) is to support new and innovative ocular epidemiology research.

The National Eye Institute (NEI) supports large-scale clinical vision research projects, including randomized clinical trials and epidemiologic studies. At the time of submission, applications requesting support for these activities are expected to provide detailed information regarding the study rationale, design, analytic techniques, protocols and procedures, facilities and environment, organizational structure, and collaborative arrangements. This information is best conveyed in a well-documented Manual of Procedures (MOP), the development of which represents a costly and time-consuming activity. This FOA is designed to facilitate activities central to the refinement of a study protocol and procedures and the development of a detailed MOP. The NEI Clinical Study Planning Grant may be used to support the development of a MOP, as well as to conduct preliminary studies to refine study procedures or document recruitment potential. The grant must not be used to generate data on the effects of a proposed intervention. This NEI FOA is applicable to both epidemiologic and clinical trial research studies.

The purpose of the U.S.-China Program for Biomedical Collaborative Research is to stimulate collaborative basic, translational, and clinical research between United States (U.S.)-based researchers and Chinese researchers in the areas of cancer, environmental health, heart disease, blood disorders, diseases of the eye and visual system, mental health, and neurological disorders. Partnering U.S. and Chinese investigators must work jointly to submit identical applications to NIH and National Natural Science Foundation of China (NSFC), respectively.  U.S. investigators must respond to the announcement from NIH, including the Chinese application as an attachment, and Chinese investigators must respond to a separate funding announcement from NSFC, including the NIH application as an attachment.     

The purpose of the U.S.-China Program for Biomedical Collaborative Research is to stimulate collaborative basic, translational, and clinical research between United States (U.S.)-based researchers and Chinese researchers in the areas of cancer, environmental health, heart disease, blood disorders, diseases of the eye and visual system, mental health, and neurological disorders. Partnering U.S. and Chinese investigators must work jointly to submit identical applications to NIH and National Natural Science Foundation of China (NSFC), respectively. U.S. investigators must respond to the announcement from NIH, including the Chinese application as an attachment, and Chinese investigators must respond to a separate funding announcement from NSFC, including the NIH application as an attachment.

The purpose of this Funding Opportunity Announcement (FOA) is to invite applications for short-term, proof-of-principle research projects that will provide preliminary data for a future FOA aimed at the development of new models that emulate human visual system anatomy, physiology and disease processes.

The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications from the scientific community to support outstanding research in the area of epitranscriptomics, i.e., the chemical modifications of RNA. Evidence is accumulating that RNA modifications regulate the function of both coding and noncoding RNAs, suggesting that these modifications are involved in both development, and in health and disease. Yet the extent and types of these RNA modifications as well as their roles in particular biological processes remain either poorly understood or not known. The goal of the FOA is to promote research into the role of RNA chemical modifications in the initiation and progression of various developmental processes and disease states and conditions relevant to the scientific mission of the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), the National Cancer Institute (NCI), and the National Eye Institute (NEI).